Proprietary microbial platform to make therapeutic antibodies for treating Priority Pathogens and other diseases, in a faster, cheaper and better way

Proprietary microbial platform to make therapeutic antibodies for treating Priority Pathogens and other diseases, in a faster, cheaper and better way

Wednesday, September 30, 2020 9:05 PM to 9:20 PM · 15 min. (Africa/Abidjan)

Bioprocessing & Manufacture

Platform Technology

Information

Topics

Topics

Infectious Diseases

ConagenConagen’s strain development, fermentation, and scale-up technologies deliver products which enhance the sales, production and profitability of our global partners across a broad spectrum of current and developing markets including pharmaceuticals. Our new proprietary microbial platform is enabled with faster, better and cheaper production of vaccines. Monoclonal antibodies and biopharmaceuticals for a wide range of therapeutic areas.

Log in

See all the content and easy-to-use features by logging in